Influvac Sub-Unit Tetra

B/Phuket/3073/2013-like virus, the active ingredient in Influvac Sub-Unit Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to prevent influenza caused by influenza virus types A and B in eligible populations.

GNH USA supplies Influvac Sub-Unit Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Influvac Sub-Unit Tetra is a quadrivalent subunit influenza vaccine used to prevent seasonal influenza infections.

- Seasonal influenza (A and B): reduces the incidence of laboratory‑confirmed influenza and associated complications. - High‑risk groups (elderly, chronic disease patients): provides protective immunity to lower hospitalization rates. - Children ≥ 6 months: induces antibody response to prevent flu‑related illness in pediatric populations.

Common and rare adverse reactions may occur after administration of Influvac Sub-Unit Tetra.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild headache within 24 hours. - Myalgia: muscle aches lasting up to two days. - Fatigue: temporary tiredness post‑vaccination.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder reported after influenza vaccination. - Seizures: infrequent convulsive episodes. - High‑grade fever: persistent fever above 39 °C.

Prior to vaccination, healthcare professionals should consider the following precautions for Influvac Sub-Unit Tetra.

- Pregnancy: safety not established; vaccinate only if benefits outweigh potential risks. - Age: indicated for individuals 6 months of age and older. - Allergy: avoid in persons with known hypersensitivity to any vaccine component. - Immunocompromised: vaccine may elicit a reduced immune response; assess benefit‑risk. - Concurrent vaccines: may be administered with other inactivated vaccines at separate sites. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before administering Influvac Sub-Unit Tetra.

Major Interactions (Avoid): - Severe hypersensitivity to a previous dose: contraindicates further administration. - Live attenuated vaccines given concurrently: may interfere with immune response; avoid simultaneous use.

Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., oseltamivir) started within 48 hours of vaccination: may reduce immunogenicity. - Immunoglobulin therapy or blood products administered within 3 weeks: may diminish antibody response. - High‑dose corticosteroids or other immunosuppressants: may lower vaccine efficacy.